Home  /  Resource Library  /  Real-world clinical outcomes of tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma: a single-center retrospective study

Real-world clinical outcomes of tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma: a single-center retrospective study

Real world study examined CAR-T tisagenlecleucel for treatment of relapsed DLBCL.